- Home
- SUGP vs UBX Comparison
SUGP vs UBX Comparison
Compare SUGP & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUGP
- UBX
- Stock Information
- Founded
- SUGP 1998
- UBX 2009
- Country
- SUGP Hong Kong
- UBX United States
- Employees
- SUGP N/A
- UBX N/A
- Industry
- SUGP
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- SUGP
- UBX Health Care
- Exchange
- SUGP NYSE
- UBX Nasdaq
- Market Cap
- SUGP 20.3M
- UBX 16.5M
- IPO Year
- SUGP 2024
- UBX 2018
- Fundamental
- Price
- SUGP $1.17
- UBX $1.73
- Analyst Decision
- SUGP
- UBX Strong Buy
- Analyst Count
- SUGP 0
- UBX 2
- Target Price
- SUGP N/A
- UBX $7.00
- AVG Volume (30 Days)
- SUGP 510.4K
- UBX 303.9K
- Earning Date
- SUGP 01-28-2025
- UBX 11-04-2024
- Dividend Yield
- SUGP N/A
- UBX N/A
- EPS Growth
- SUGP N/A
- UBX N/A
- EPS
- SUGP 0.10
- UBX N/A
- Revenue
- SUGP $20,252,232.00
- UBX N/A
- Revenue This Year
- SUGP N/A
- UBX N/A
- Revenue Next Year
- SUGP N/A
- UBX $33.62
- P/E Ratio
- SUGP $11.40
- UBX N/A
- Revenue Growth
- SUGP N/A
- UBX N/A
- 52 Week Low
- SUGP $0.76
- UBX $0.94
- 52 Week High
- SUGP $5.86
- UBX $2.02
- Technical
- Relative Strength Index (RSI)
- SUGP 46.38
- UBX 63.32
- Support Level
- SUGP $1.09
- UBX $1.56
- Resistance Level
- SUGP $1.26
- UBX $1.85
- Average True Range (ATR)
- SUGP 0.14
- UBX 0.22
- MACD
- SUGP 0.01
- UBX 0.05
- Stochastic Oscillator
- SUGP 34.15
- UBX 75.96
About SUGP SU GROUP HLDGS LTD
SU Group Holdings Ltd and its subsidiaries is an integrated security-related services company. The company has two reportable segments: security-related engineering services, and security guarding and screening services and related vocational training services. The company generates the majority of its revenue from the security-related engineering services segment.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.